Advertisement
Advertisement
-
TOPIC

Biomedicine: Industry Trends

Related Topics:
Biomedicine: Industry Trends
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
The combined daily production capacity of ibuprofen and paracetamol in China surged fourfold to 202 million tablets by late December 2022. Photo: Shutterstock
Made in China 2025

After boost from viral dance challenge, Chinese medicine firm’s shares languish

Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.

China’s private sector

Lab monkey price tag climbs to US$20,000 thanks to China’s biotech boom

Made in China 2025

Capital injection: China backs AI drug makers in self-reliance drive

Made in China 2025

Chinese healthcare firms expand overseas to support growing expat community

Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.

Distinct Healthcare raised HK$284.53 million from its initial public offering in Hong Kong last week. Photo: Handout
Banking & finance

Mainland China’s investors pour into Hong Kong-listed drug stocks

An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.

China’s private sector

Biomedicine | China challenges US in new drugs after industry transformation

Drug makers in China are performing cutting-edge research and licensing products to global giants after a 10-year government push supercharged the industry.

Advertisement
Advertisement
Advertisement
Made in China 2025

Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal

The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.

A view of the Shanghai facility of Fosun Pharma’s biopharma unit Henlius. Photo: Handout
IPO

Morgan Stanley sees another record year for Hong Kong IPOs as pipeline hits 450

Mainland China’s issuers will still dominate city’s IPO market, executive says, but US and Southeast Asian companies are also joining in.

Biomedicine: Geopolitics

China could approve first AI-designed drug next year, Merck executive says

AI and genetics are creating a ‘seismic shift’ in the pharmaceutical business, experts on Asian Financial Forum panel say.

Banking & finance

Global funds, from BlackRock to Temasek, back China’s largest biotech firms

Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne.

Global investors have reaped sizeable rewards from their investments in Hong Kong-listed biotech and pharmaceutical companies in the past year. Photo: Shutterstock
Biomedicine: Geopolitics

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.

Global drug companies no longer view Chinese firms as contract manufacturers, but as development partners, an analyst says. Photo: Shutterstock
Made in China 2025

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

Hong Kong economy

Editorial | Hong Kong’s biotech hub aim advanced by pacts with national agencies

Deepening cooperation on traditional Chinese medicine and cancer research will help the city play a role in developing more effective and less intrusive treatments.

Made in China 2025

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Swiss drugmaker Novartis has gained global rights over SciNeuro’s novel amyloid beta targeted antibody programme. Photo: Reuters
Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

There were more than 400 million overweight or obese adults in China in 2021, according to a study. Photo: Getty Images
Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

Advertisement
Advertisement
Advertisement
Insilico

Insilico signs US$888 million AI drug deal days after Hong Kong IPO

Multi-year partnership with France’s Servier will use Insilico’s AI platform to explore novel cancer drugs.

The deal further validates Insilico’s AI-driven drug discovery platform, which the company claims can slash drug-development timelines to 12 to 18 months from the average of 4.5 years. Photo: Shutterstock
Banking & finance

The ‘biology winter’ thaws: why investors are buying Hong Kong’s biotech IPOs

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are surging.

Science

China’s biopharma sector ‘in prime position to challenge US leadership’

American commission issues stark warning, as analytics firm Clarivate reports that Chinese innovative drug development has entered new phase.

videocam
33
IPO

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.

Insilico is training and testing an AI-powered drug-discovery tool to enable faster, cheaper and more successful drug discovery. Photo: Handout
Made in China 2025

China’s rising biotech clout on show in flurry of billion-dollar licensing deals

A burst of overseas licensing pacts is spotlighting China’s biotech sector, as Jacobio, Coherent Biopharma and Harbour BioMed land deals.

The latest transactions reflect a broader pattern of multinational drugmakers turning to Chinese biotechs for pipeline replenishment. Photo: Shutterstock
Banking & finance

Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG

Survey of multinational corporations finds optimism in life sciences, healthcare and manufacturing, with half forecasting revenue growth.

United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

China is gaining a solid reputation as a pharmaceutical innovation hub, according to global consultancy Idea Pharma. Photo: AP
Made in China 2025

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

The commercial insurance formulary covers some medicines that are not yet eligible for reimbursement under the country’s National Reimbursement Drug List. Photo: Shutterstock
Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

Science

Sperm quality decline: could easy-to-use balm from China solve the crisis?

In China, unhealthy lifestyles, pollution and work-related stress are cited in public health discussions around declining sperm quality.

videocam
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement